Vitaspring Biomedical Co. Ltd.

VSBC OTC SEC CIK 1697884
Follow Vitaspring Biomedical Co. Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2027 USD · US GAAP
Revenue, last quarter $0
Net income −$155.8K −40.6% vs same quarter last year
EPS, diluted $0.00
Operating cash flow $5.2K +538.4% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$5M−$2.5M$0$2.5M$5M$7.5MFY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26$0−$415.4K
FY25$0−$774.9K
FY24$0−$1.1M
FY23$0−$4.2M
FY22$5.6M$909.6K
FY21$248.2K$425.4K
FY20$15.1K$6.9K
FY19$17.2K−$22.4K
FY18$16.2K−$6.4K
FY17$0−$45
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%200%FY18FY20FY22FY24FY26
Show the numbers
YearGross marginOperating marginNet margin
FY26---
FY25---
FY24---
FY23---
FY2236.8%20.1%16.2%
FY2145.2%171.4%171.4%
FY2011.2%45.7%45.7%
FY1979.8%−130.4%−130.4%
FY1869.9%−39.3%−39.3%
FY17---
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Vitaspring Biomedical Co. Ltd.
  • Healthcare median
−200%−100%0%100%200%FY18FY20FY22FY24FY26
Show the numbers
YearVitaspring Biomedical Co. Ltd.Healthcare median
FY26-−11.1%
FY25-−30.6%
FY24-−47%
FY23-−58%
FY2216.2%−80.4%
FY21171.4%−71.9%
FY2045.7%−62.2%
FY19−130.4%−46.3%
FY18−39.3%−49.6%
FY17-−45.9%